Suicide Attempt by Pure Citalopram Overdose Causing Long-lasting Severe Sinus Bradycardia, Hypotension and Syncopes: Successful Therapy with a Temporary Pacemaker

In few cases, pure citalopram overdose at doses above 600 mg showed electro-cardiographic changes with prolonged QT intervals and sinus bradycardia gradually resolving within 12 - 24 hours after intoxication. We report on a 32-year-old patient with borderline personality disorder (BPD) who ingested a total of 800 mg citalopram to attempt suicide due to an interpersonal disappointment. She developed severe sinus bradycardia with a minimal pulse rate of 41/min within about 4 hours after intoxication lasting up to six days during intensive care unit (ICU) treatment. Further, hypotension and syncopes occurred. No QT interval prolongations were recorded. To our knowledge, this is the first case report of pure citalopram overdose-induced long-lasting sinus bradycardia associated with severe hypotension and intermittent syncopes that required therapy with a temporary pacemaker.

References

• 1 Barbey J T, Roose S P. SSRI safety in overdose.  J. Clin. Psychiatry. 1998;  59 Suppl 15 42-48
• 2 Bazett H C. An analysis of the time-relations of electrocardiograms.  Heart. 1920;  7 353-370
• 3 Boeck V, Jørgensen A, Overø K F. Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels.  Psychopharmacology. 1984;  82 275-281
• 4 Brion F, Brion N, Durigon M. Fatal overdose with citalopram?.  The Lancet. 1996;  348 1380
• 5 Coumel P. The fuzzy set of long QT intenral, torsade de pointes and the autonomic nervous system. In: Butrous, G.S., P. Schwartz (Eds.): Clinical aspects of ventricular repolarization. London: Farrand Press 1989: 311
• 6 Freemantle N, House A, Song F, Mason J, Sheldon T. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide.  Br. Med. J.. 1994;  309 249-253
• 7 Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F. Symptoms and signs of severe citalopram overdose.  The Lancet. 1997;  349 1602
• 8 Henry J, Alexander C, Sener E. Relative mortality from overdose of antidepressants.  Br. Med. J.. 1995;  310 221-224
• 9 Hyttel J. Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.  Prog. Neuropsychopharmacol. Biol. Psychiatry. 1982;  6 277-295
• 10 Isacsson G, Bergman U. Risks with citalopram in perspective.  The Lancet. 1996;  348 1033
• 11 Kapfhammer H P, Hippius H. Special feature: Pharmacotherapy in personality disorders.  Journal of Personality Disorders. 1998;  12 277-288
• 12 Klein-Schwartz W, Anderson B. Analysis of sertraline-only overdoses.  Am. J. Emerg. Med.. 1996;  14 456-458
• 13 Lepola U, Leinonen E, Koponen H. Serum drug levels and electroencephalographic findings after citalopram intoxication.  Nord. J. Psychiatry. 1996;  50 61-62
• 14 Mendelowitz A, Dawkins K, Lieberman J A. Antidepressants.  In: J.A. Lieberman, A. Tasman (eds.): Psychiatric drugs. W.B. Saunders Company, Philadelphia 2000: 72-75
• 15 Muldoon C. The safety and tolerability of citalopram.  International Clinical Psychopharmacology. 1996;  11 (Suppl. 1) 35-40
• 16 Ohberg A, Vuori E, Klaukka T, Lonnqvist J. Antidepressants and suicide mortality.  Journal of Affective Disorders. 1998;  50 225-233
• 17 Öström M, Eriksson A, Thorson J, Spigset O. Fatal overdose with citalopram.  The Lancet. 1996;  348 339-340
• 18 Personne M, Sjöberg G, Persson H. Citalopram overdose - review of cases treated in Swedish hospitals.  Clinical Toxicology. 1997;  35 237-240
• 19 Power A. Drug treatment of depression. Citalopram in overdose may result in serious morbidity and death.  British Medical Journal. 1998;  316 307-308
• 20 Rich C, Isacsson G. Suicide and antidepressants in South Alabama: evidence for improved treatment of depression.  J. Affect. Disord.. 1997;  45 135-142
• 21 Rothenhäusler H B, Kapfhammer H P. Der Verlauf von Borderline-Störungen.  Fortschritte der Neurologie Psychiatrie. 1999;  67 200-217
• 22 Sindrup S H, Brosen K, Hansen M G J, Aes-Jorgensen T, Overo K, Gram L F. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.  Ther. Drug Monit.. 1993;  15 11-7
• 23 Zehender M, Hohnloser S, Just H. QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.  Cardiovascular Drugs and Therapy. 1991;  5 515-530